Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy

American Journal of Transplantation

Volumn 11, Issue 3, 2011, Pages 511-517

  Saab, Sammy ^a   Desai, S ^a   Tsaoi, D ^b   Durazo, F ^a   Han, S ^a   McClune, A ^a   Holt, C ^a   Farmer, D ^a   Goldstein, L ^a   Busuttil, R W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Hepatitis B recurrence; Liver transplantation

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADMINISTRATION, ORAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 79951992823     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03416.x     Document Type: Article

References (21)

1. Jiang L, Yan L, Li B et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. AmJ Transplant 2010; 10: 1861-1869.
2. Han SH, Ofman J, Holt C, King K et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
3. Buti M, Mas A, Prieto M et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650-654. (Pubitemid 47429048)
4. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937. (Pubitemid 46440868)
5. Steinmüller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-1535. (Pubitemid 34966909)
6. Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 2003; 7: 537-550. (Pubitemid 37093417)
7. Dan YY,Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis. Liver Transpl 2006; 12: 736-746.
8. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. Hepatology 2000; 32: 1189-1195.
9. Castells L, Vargas V, Rodríguez F et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002; 8: 892-900.
10. Westland CE, Yang H, Delaney WE et al. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J Viral Hepat 2005; 12: 67-73. (Pubitemid 40188776)
11. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
12. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-813. (Pubitemid 40975583)
13. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006; 20: 206-210.
14. Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130-2134. (Pubitemid 350145596)
15. Vierling JM. Management of HBV infection in liver transplantation patients. Int J Med Sci 2005; 2: 41-49. (Pubitemid 40944950)
16. Neff GW, Kemmer N, Kaiser TE et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52: 2497-2500. (Pubitemid 47373893)
17. Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009; 15: 413-420.
18. Saab S, Yeganeh M, Nguyen K et al. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15: 1525-1534.
19. Shiffman ML, Stravitz RT, Kimmel M, Sterling RK, Luketic VA, Fisher RA. Tenofovir plus emtricitabine (truvada) prevents recurrence of hepatitis B virus (HBV) in liver transplant (LT) recipients after discontinuing hepatitis B immune globulin (HBIg) [abstract]. Hepatology 2009; 50: 392A.
20. Vassiliadis TG, Giouleme O, Koumerkeridis G et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: A 4-year study. J Gastroenterol Hepatol 2010; 25: 54-60.
21. Schiff E, Lai CL, Hadziyannis S et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. Liver Transpl 2007; 13: 349-360. (Pubitemid 46444463)